WO2017077391A3 - Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles - Google Patents

Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles Download PDF

Info

Publication number
WO2017077391A3
WO2017077391A3 PCT/IB2016/001726 IB2016001726W WO2017077391A3 WO 2017077391 A3 WO2017077391 A3 WO 2017077391A3 IB 2016001726 W IB2016001726 W IB 2016001726W WO 2017077391 A3 WO2017077391 A3 WO 2017077391A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
periostin
dipeptidyl peptidase
eosinophilic
eosinophil
Prior art date
Application number
PCT/IB2016/001726
Other languages
English (en)
Other versions
WO2017077391A2 (fr
Inventor
Paul NEWBOLD
Ranade Koustubh
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to EP16822517.5A priority Critical patent/EP3371225A2/fr
Priority to JP2018521654A priority patent/JP2018538249A/ja
Priority to CA3002761A priority patent/CA3002761A1/fr
Priority to AU2016349113A priority patent/AU2016349113A1/en
Publication of WO2017077391A2 publication Critical patent/WO2017077391A2/fr
Publication of WO2017077391A3 publication Critical patent/WO2017077391A3/fr
Priority to HK18114988.5A priority patent/HK1255922A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La présente invention concerne l'utilisation de niveaux d'expression génétique et/ou protéinique de la dipeptidyl peptidase-4 (DPP4/CD26) et de la périostine (POSTN) en tant que biomarqueurs périphériques pour des maladies ou des troubles éosinophiles, par exemple de l'asthme modéré à sévère. Des niveaux de DPP4 et/ou de POSTN supérieurs ou inférieurs à des niveaux seuils prédéfinis de DPP4 et/ou de POSTN peuvent être utilisés, par exemple, (i) pour déterminer l'éligibilité d'un patient à un certain traitement avec un antagoniste de l'IL-5R, par exemple, un anticorps anti-IL-5R tel que le benralizumab (MEDI-563), (ii) pour déterminer si un certain traitement d'une maladie ou d'un trouble éosinophile avec un antagoniste spécifique de l'IL-5R devrait être initié, arrêté ou modifié, (iii) pour diagnostiquer si une maladie ou un trouble éosinophile peut être traité ou non avec un antagoniste spécifique de l'IL-5R, (iv) pour établir un pronostic du résultat du traitement d'une maladie ou d'un trouble éosinophile avec un antagoniste spécifique de l'IL-5R, etc.
PCT/IB2016/001726 2015-11-04 2016-11-03 Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles WO2017077391A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP16822517.5A EP3371225A2 (fr) 2015-11-04 2016-11-03 Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles
JP2018521654A JP2018538249A (ja) 2015-11-04 2016-11-03 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
CA3002761A CA3002761A1 (fr) 2015-11-04 2016-11-03 Dipeptidyl peptidase-4 et periostine utilisees comme predicteurs d'une reponse clinique a des agents therapeutiques cibles sur les eosinophiles dans des maladies eosinophiles
AU2016349113A AU2016349113A1 (en) 2015-11-04 2016-11-03 Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
HK18114988.5A HK1255922A1 (zh) 2015-11-04 2018-11-23 二肽基肽酶-4和骨膜素作為嗜酸性粒細胞疾病中嗜酸性粒細胞靶向治療藥物臨床反應的預測因子

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250691P 2015-11-04 2015-11-04
US62/250,691 2015-11-04

Publications (2)

Publication Number Publication Date
WO2017077391A2 WO2017077391A2 (fr) 2017-05-11
WO2017077391A3 true WO2017077391A3 (fr) 2017-06-29

Family

ID=57737757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/001726 WO2017077391A2 (fr) 2015-11-04 2016-11-03 Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d'une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles

Country Status (6)

Country Link
EP (1) EP3371225A2 (fr)
JP (1) JP2018538249A (fr)
AU (1) AU2016349113A1 (fr)
CA (1) CA3002761A1 (fr)
HK (1) HK1255922A1 (fr)
WO (1) WO2017077391A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020049026A1 (fr) * 2018-09-05 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions de traitement de l'asthme et de maladies allergiques
KR102527520B1 (ko) * 2020-09-16 2023-05-03 순천대학교 산학협력단 직업성 천식 진단용 조성물 및 이를 이용한 직업성 천식 진단방법
AU2022349077A1 (en) * 2021-09-22 2024-03-28 Sonoma Biotherapeutics, Inc. Il5ra cell surface markers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104216A2 (fr) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
WO2008091814A2 (fr) * 2007-01-22 2008-07-31 Wyeth Évaluation de l'asthme et d'une expression d'un gène dépendant d'un allergène
WO2015112970A1 (fr) * 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) comme biomarqueur périphérique de l'activation de l'il-13 dans des poumons asthmatiques

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
TW311927B (fr) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
ES2450929T3 (es) 2004-10-29 2014-03-25 Topigen Pharmaceuticals Inc. Oligonucleótidos antisentido para tratar la alergia y la proliferación de las células neoplásicas
WO2007098065A2 (fr) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Isoformes de canaux sodium humains
NZ741494A (en) 2007-05-14 2022-11-25 Kyowa Kirin Co Ltd Methods of reducing eosinophil levels
US7879553B2 (en) 2008-03-14 2011-02-01 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
AU2009231733B2 (en) 2008-03-31 2015-12-24 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
WO2010027766A1 (fr) 2008-08-27 2010-03-11 Schering Corporation Formulations lyophilisées d'anticorps anti-il-23p19 modifiés
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010042903A1 (fr) 2008-10-09 2010-04-15 Alfagene Bioscience, Inc Utilisation et identification de biomarqueurs pour les maladies gastro-intestinales
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
WO2010129964A1 (fr) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Cibles de médicament pour la prévention de l'arythmie dans une maladie cardiaque
AU2010266028B2 (en) 2009-06-25 2015-04-30 Société des Produits Nestlé S.A. Methods for diagnosing irritable bowel syndrome
CA2781654A1 (fr) 2009-11-25 2011-06-03 Hua Gong Nouveaux biomarqueurs genomiques utilises dans le diagnostic du syndrome du colon irritable
MY182680A (en) 2010-01-15 2021-01-29 Amgen K A Inc Antibody formulation and therapeutic regimens
BR112013013460A8 (pt) 2010-12-16 2019-02-12 Genentech Inc métodos de identificação de um paciente com asma, método de monitoramento de um paciente com asma, uso de um kit de detecção de periostina total, kit de medição da periostina total, uso de um anticorpo anti-il-13, uso de uma quantidade terapeuticamente eficaz de lebrikizumab, uso de um inibidor da via de th2, método de avaliação de eventos adversos, anticorpo anti-periostina e teste de periostina total
BR112013017445A2 (pt) 2011-01-06 2016-08-23 Univ Illinois métodos de determinar a necessidade de um indivíduo para um desfibrilador cardíaco implantado (icd) e para uma terrapia antiarrítmica, de determinar o risco de um indivíduo para uma morte cardiáca súbita, para arritmias e para insuficiência cardíaca, de reduzir risco de morte cardíaca súbita em um indivíduo, kit, sistema, meio de armazenamento legível por computador, e, método implementado por um processador em um computador
WO2012158831A1 (fr) 2011-05-16 2012-11-22 Prometheus Laboratories Inc. Efficacité d'un panel de biomarqueurs du syndrome du côlon irritable
US8961965B2 (en) 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US9732387B2 (en) 2012-04-03 2017-08-15 The Regents Of The University Of Michigan Biomarker associated with irritable bowel syndrome and Crohn's disease
CN111617244A (zh) 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
US9441037B2 (en) 2013-08-12 2016-09-13 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
KR20160125409A (ko) 2014-02-07 2016-10-31 메디뮨 엘엘씨 인간 페리오스틴을 검출하기 위한 신규 검정법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104216A2 (fr) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
WO2008091814A2 (fr) * 2007-01-22 2008-07-31 Wyeth Évaluation de l'asthme et d'une expression d'un gène dépendant d'un allergène
WO2015112970A1 (fr) * 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) comme biomarqueur périphérique de l'activation de l'il-13 dans des poumons asthmatiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER E BRIGHTLING ET AL: "Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study", THE LANCET. RESPIRATORY MEDICINE, vol. 2, no. 11, 1 November 2014 (2014-11-01), Oxford, pages 891 - 901, XP055372120, ISSN: 2213-2600, DOI: 10.1016/S2213-2600(14)70187-0 *
KOIKE M ET AL: "Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity - IOS Press", 1 January 2009 (2009-01-01), XP055372114, Retrieved from the Internet <URL:http://content.iospress.com/articles/human-antibodies/hab00198> [retrieved on 20170512] *
STEFANO MOLICA ET AL: "Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia", EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 83, no. 3, 1 September 2009 (2009-09-01), pages 208 - 214, XP055215021, ISSN: 0902-4441, DOI: 10.1111/j.1600-0609.2009.01273.x *

Also Published As

Publication number Publication date
EP3371225A2 (fr) 2018-09-12
AU2016349113A1 (en) 2018-06-07
HK1255922A1 (zh) 2019-09-06
WO2017077391A2 (fr) 2017-05-11
JP2018538249A (ja) 2018-12-27
CA3002761A1 (fr) 2017-05-11

Similar Documents

Publication Publication Date Title
Revuelta et al. Autophagy in stem cell aging
Witcher et al. Traumatic brain injury‐induced neuronal damage in the somatosensory cortex causes formation of rod‐shaped microglia that promote astrogliosis and persistent neuroinflammation
Srini et al. Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population
Kijima et al. Molecular classification of medulloblastoma
WO2005112981A3 (fr) Compositions et methodes permettant de stimuler ou de renforcer l&#39;osteoformation et l&#39;autorenouvellement des cellules
MX2016009491A (es) Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.
WO2012083132A3 (fr) Diagnostic et traitements associés à l&#39;inhibition de th2
WO2016077366A8 (fr) Méthodes thérapeutiques et diagnostiques pour les troubles à médiation par l&#39;il-33
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
Liu et al. Reduced scleral TIMP-2 expression is associated with myopia development: TIMP-2 supplementation stabilizes scleral biomarkers of myopia and limits myopia development
EP2687220A3 (fr) Traitement de maladies inflammatoires au moyen de cellules souches placentaires
WO2007053661A3 (fr) Utilisations d&#39;anticorps anti-cd40
WO2009043159A8 (fr) Cellules souches tumorales neurales et leurs procédés d&#39;utilisation
WO2017077391A3 (fr) Dipeptidyl peptidase-4 et périostine utilisées comme prédicteurs d&#39;une réponse clinique à des agents thérapeutiques ciblés sur les éosinophiles dans des maladies éosinophiles
WO2009028870A3 (fr) Composition pour le diagnostic, la prévention ou le traitement de maladies liées à l&#39;expression il-8 ou gro-alpha de cellules, comprenant des cellules souches mésenchymateuses ucb
AU2011270668A8 (en) CNS delivery of therapeutic agents
MY164376A (en) Phosphospecific antibodies recognizing tau
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
Gaublomme et al. Matrix metalloproteinase 2 and membrane type 1 matrix metalloproteinase co‐regulate axonal outgrowth of mouse retinal ganglion cells
EP2563794A4 (fr) Inhibiteurs de l&#39;activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
MX2021013974A (es) Metodos, sistemas y dispositivos de seleccion de pacientes tl1a.
Godse Omalizumab in treatment-resistant chronic spontaneous urticaria
WO2020176654A8 (fr) Utilisation de la fonction de la protéase caséinolytique p en tant que biomarqueur de réponse médicamenteuse à des agents de type imipridone
WO2011028880A3 (fr) Procédé d&#39;amélioration de la stabilité du génome et de l&#39;élongation du télomère dans des cellules souches embryonnaires
WO2009095454A3 (fr) Procédé d&#39;identification de patients présentant de légers troubles cognitifs, nécessitant un traitement, et traitement de ces patients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16822517

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3002761

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2018521654

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016822517

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016349113

Country of ref document: AU

Date of ref document: 20161103

Kind code of ref document: A